Intranasal Exposure to Rift Valley Fever Virus Live-Attenuated Strains Leads to High Mortality Rate in Immunocompetent Mice

Sandra Lacote 1, Carole Tamietti 2, Mehdi Chabert 3,†, Marie-Pierre Confort 3,†, Laurine Conquet 4, Coralie Pulido 5, Noémie Aurine 6, Camille Baquerre 6, Adrien Thiesson 3, Bertrand Pain 6, Marcelo De Las Heras 7,⁎, Marie Flamand 2, Xavier Montagutelli 4, Philippe Marianneau 1, Maxime Ratinier 3,† and Frédéric Arnaud 3,†,‡

Abstract: Rift Valley fever virus (RVFV) is a pathogenic arthropod-borne virus that can cause serious illness in both ruminants and humans. The virus can be transmitted by an arthropod bite or contact with contaminated fluids or tissues. Two live-attenuated veterinary vaccines—the Smithburn (SB) and Clone 13 (Cl.13)—are currently used during epizootic events in Africa. However, their residual pathogenicity (i.e., SB) or potential of reversion (i.e., Cl.13) causes important adverse effects, strongly limiting their use in the field. In this study, we infected immunocompetent mice with SB or Cl.13 by a subcutaneous or an intranasal inoculation. Interestingly, we found that, unlike the subcutaneous infection, the intranasal inoculation led to a high mortality rate. In addition, we detected high titers and viral N antigen levels in the brain of both the SB- and Cl.13-infected mice. Overall, we unveil a clear correlation between the pathogenicity and the route of administration of both SB and Cl.13, with the intranasal inoculation leading to a stronger neurovirulence and higher mortality rate than the subcutaneous infection.

Keywords: Rift Valley fever virus; attenuated vaccine strains; intranasal exposure; pathogenicity

1. Introduction

Rift Valley fever virus (RVFV) is a zoonotic and hemorrhagic fever virus that infects both ruminants (mainly sheep and cattle) and humans. In the former, it causes high mortality rates in new-born animals and massive abortions in pregnant females (with, sometimes, a 100% prevalence) while, in the latter, it leads to milder symptoms characterized by a self-limiting, acute, febrile illness [1–4]. In 1 to 3% of cases, however, patients develop more severe diseases such as fulminant hepatitis associated with hemorrhage and, occasionally, retinitis or late-onset encephalitis, with a fatality rate in hospitalized patients that ranges from 10 to 20%, depending on the epidemics [5–7].

RVFV is an arthropod-borne virus (arbovirus) naturally transmitted by infected mosquitoes belonging to the Aedes and Culex genera, even though it can be found in an unusual broad spectrum of arthropod species, including blackflies (Simulium spp.), midges (Culicoides spp.), tropical bent ticks (Amblyomma variiegatum), and several species of mosquitoes and sand flies (Phlebotomus spp.) [3,8,9]. The virus can also spread via aerosol or direct contact with the organs or fluids of infected animals. For these reasons, certain
professions such as veterinarians, farmers, and slaughterhouse workers are at higher risk of infection [10,11]. The World Health Organization has classified RVFV in the top ten priority list of emerging pathogens likely to cause severe outbreaks in the future. Until recently, indeed, RVFV periodic epidemics mainly occurred in sub-Saharan Africa, however, in recent decades, due to climate changes, they extended to the Arabian Peninsula, causing major economic losses in animal husbandry and thousands of human deaths [12–15]. The wide range and abundance of its host species alongside the possibility of infection by aerosol exposure make RVFV a major threat for humans and livestock, as well as a potential agent of bioterrorism; vaccination is therefore key to prevent a viral spread. To date, however, no licensed RVFV vaccine or treatment has been developed for human use, while three veterinary vaccines are currently available on the market: one formalin-inactivated, derived from an ancient strain, and two live-attenuated vaccines—the Smithburn (SB) and the Clone 13 (Cl.13) strains—which are widely used in endemic countries during epizootics [16,17].

The SB strain was the first vaccine to be developed against RVFV, in 1949, via the serial intracerebral passages of the pathogenic Entebbe strain in mice [11]. It is mainly used in eastern and southern Africa, and it is quite effective as it is able to induce a long-term protective immunity with a single dose [17]. However, it is not very safe as it retains a residual pathogenicity that can provoke abortions and fetal malformations in pregnant females [18]. For these reasons, the SB vaccine strain is recommended only in non-pregnant animals in RVFV endemic countries before and after outbreaks [17]. The Cl.13 strain was isolated from a plaque clone of the RVFV 74HB59 strain recovered from a patient of the Central African Republic [19]. Since 2010, it is a registered veterinary vaccine, increasingly used in western Africa [16]. Interestingly, the Cl.13 strain displays a large deletion in the open reading frame of the viral non-structural protein NSs [19]. NSs is the main virulence factor of RVFV as it strongly antagonizes the type-I interferon synthesis and inhibits the general host transcription by perturbing the assembly of the transcription factor II human (TFIIH) complex [20]. The Cl.13 live-attenuated vaccine appears to be safer than SB, even if, at high doses, it causes abortions [21].

Mice represent good, convenient, and well-established animal models to study the routes of transmission, the mechanisms of spread to target organs, and virulence of RVFV [22]. Along this line, RVFV-infected mice display important similarities to severe human infections with, depending on the mouse genetic background, extensive and fatal liver damages or delayed-onset encephalitis [23]. Moreover, they share the same RVFV tissue tropism and target cells with humans. Indeed, RVFV infects human and murine dendritic cells and macrophages, which probably facilitates a virus dissemination to various organs, potentially through the blood vessels [24,25]. Subsequently, RVFV disseminates to several tissues, including the liver, where it infects the hepatocytes and stellate cells. Occasionally, the virus reaches the central nervous system, where it is detectable in both the neurons and astrocytes of infected mice [22]. Notably, RVFV can also target the olfactory neurons lining the nasal tract and, in mice, aerosol exposure to RVFV results in an earlier and more severe neuropathology compared to a subcutaneous (SC) inoculation [26–29]. Interestingly, a recent study demonstrated that, in cattle, the intranasal administration of a Kenyan pathogenic RVFV strain induces a higher and long-lasting viremia and stronger clinical signs compared to an intradermal or SC inoculation [30]. On the other hand, an attenuated RVFV lacking the NSs sequence has been shown to cause severe and lethal neurological diseases in immunocompetent mice, only when infected intranasally and not subcutaneously [31]. Moreover, one study has shown that the Cl.13 intranasally (IN)-infected mice developed lethal encephalitis within 11 days post-infection, although they did not compare the IN route with the SC inoculation [32]. Overall, little is known on the impact of the route of transmission on RVFVs pathogenicity, particularly on that of the SB and Cl.13 vaccine strains. Unveiling this process is very important, not only to better understand the mechanisms underlying the efficacy and safety of these vaccines, but also to assess whether an aerosol exposure to RVFV may impact its pathogenicity (such as in the case of...
laboratory exposure or a bioterrorist attack). In this study, we characterized the viral titers and tissue tropism of RVFV SB and Cl.13 following an IN or SC infection, thus providing an important insight into their virulence and dissemination in immunocompetent mice.

2. Materials and Methods

2.1. Cell Cultures

BSR were kindly provided by Prof Karl Conzelmann (Ludwig-Maximilians-University Munich, Gene Center, Munich/Germany). VeroE6 cells were purchased from ATCC. The BSR and VeroE6 cells were grown in Dulbecco’s modification of an Eagle medium (DMEM) (Gibco, Thermo Fisher Scientific, Villebon-sur-Yvette, France), supplemented with 10% heat-inactivated fetal bovine serum (FBS) (GE HEALTHCARE Europe GmbH, Freiburg, Germany), and 25 µg/mL of penicillin-streptomycin (Gibco). The HepaRG cells were purchased from Lonza (Colmar, France) and grown in William’s E medium (Gibco), supplemented with 10% heat-inactivated FBS, 1% L-glutamine (Gibco), 5 µg of insulin (Gibco), and 0.5 µM of hydrocortisone (Sigma-Aldrich, Merck, Saint-Quentin Fallavier, France). Human embryonic fibroblasts (HEF) were kindly provided by Prof Odile Boespflug-Tanguy (AP-HP, Robert Debre Hospital, Department of Neuropediatrics and Metabolic Diseases, National Reference Center for Leukodystrophies, Paris, France). The HEF were grown in a fibroblast medium containing DMEM/F-12 (Gibco, Thermo Fisher Scientific), 10% fetal calf serum (Gibco, Thermo Fisher Scientific), 1X penicillin-streptomycin (Gibco, Thermo Fisher Scientific), and 2 mM of L-glutamine (Gibco, Thermo Fisher Scientific). All the cell lines were cultured in a 37 °C, 5% CO₂ humidified incubator.

2.2. Human Induced-Pluripotent Stem Cells

The HEF were reprogrammed into human-induced pluripotent stem cells (hiPSC) using a CytoTune™ Sendai Reprogramming Kit (Life Technologies, Thermo-Fisher, Illkirch-Graffenstaden, France), according to the manufacturer’s instructions. The HEF and hiPSCs were declared with the number DC-2020-3895 onto the CODECOH platform “https://appliweb.dgri.education.fr/appli_web/codecoh/IdentCodec.jsp (accessed on 18 May 2020)”. The cells were maintained in mTeSR1 (StemCell Technologies, Saint Egreve, France) on a matrigel coating (Corning, Thermo-Fisher, Illkirch-Graffenstaden, France), and dissociated with dispase (StemCell Technologies), according to the manufacturer’s instructions. Two independent isolates were used. These cells were subsequently differentiated into neurons, astrocytes, and oligodendrocytes, according to the protocol reported below.

2.3. Induction into 2D Neural Differentiation

Once dissociated, the cells were seeded into a 12-well tissue culture plate (1.5 × 10⁵ cells/mL) and grown into the neural induction medium (NIM). NIM contains DMEM/F-12 (Thermo-Fisher, Illkirch-Graffenstaden, France) and it is complemented with 2 mM of L-glutamine (Thermo-Fisher), 1000 U/mL of penicillin-streptomycin (Thermo-Fisher), 1% MEM non-essential amino acids solution (Thermo-Fisher), 1 mM of 2-mercaptoethanol (Thermo-Fisher), and 1% N-2 supplement (Thermo-Fisher). The medium was changed every two days, and replaced, on day 7, with the neural stem medium, containing NIM supplemented with 20 ng/mL of human recombinant basic Fibroblast Growth Factor (hrFGF) (154 a.a., Peprotech, Neuilly-Sur-Seine, France), and 20 ng/mL of murine recombinant Epidermal Growth Factor (mEGF) (Peprotech). The medium was changed every two days. At day 14, the medium was replaced with NIM supplemented with 0.5 µM of all-trans retinoic acid (ATRA) (Sigma-Aldrich Chimie, Saint Quentin Fallavier, France) for 4 days, and with a fresh media at day 16. At day 18, the NIM was complemented with 0.5 µM of ATRA, 2% B-27 supplement (Thermo-Fisher), and 100 ng/mL of human recombinant Sonic Hedge Hog (hrSHH) (StemCell Technologies, Saint Egreve, France). The cells were grown in this medium for 10 days, with a change every two days. At day 28, the medium was replaced with the NIM complemented with 2% B-27 supplement, 100 ng/mL of hrSHH, and 10 ng/mL of hrFGF. The cells were grown in this medium for 12 days, and
the medium was changed every two days. At day 40, the medium was adjusted again for the cells’ maturation, and supplemented with 2% B-27 supplement, 100 ng/mL of hrSHH, 10 ng/mL of human recombinant Platelet derived growth factor-AA (Peprotech), and 40 ng/mL of 3,3’,5-Triiodo-L-thyronine sodium salt (Sigma-Aldrich). The medium was changed every two days until the cells were infected and analyzed.

2.4. Virus Stocks and Titrations

RVFV SB and Cl.13 attenuated vaccines were purchased from Onderstepoort Biological Products. All the experiments with infectious RVFV SB and Cl.13 strains were carried out in biosafety level (BSL)-3 laboratories. The RVFV SB and Cl.13 viral stocks titers were determined by standard plaque assays using serial 10-fold dilutions in VeroE6 cells. Briefly, the monolayers of VeroE6 cells were plated onto 12-wells plates and infected for 2 h at 37 °C. The inocula were then removed and the cells were washed twice with phosphate-buffered saline (PBS). After, one and a half milliliters of a semisolid overlay (2.5% Agarose in 2X MEM supplemented with 4% FBS) were added on the top of the cells, and the plate was incubated at 37 °C for 3 to 5 days. Finally, the overlay was removed, and the cells were washed with PBS before being fixed with 4% paraformaldehyde and stained either using an anti-N RVFV antibody (kindly provided by Dr Benjamin Brennan, MRC-University of Glasgow Centre for Virus Research-Glasgow) [33] or with 0.2% crystal violet, 3.7% formaldehyde, and 20% ethanol solution. The viral titers are expressed as FFU/mL or PFU/mL, respectively.

2.5. Virus Growth Curves

Prior to infection, the HepaRG and neural differentiated hIPSC were seeded into 12-well and 24-well tissue culture plates (Corning), respectively. The cells were then infected with the SB or Cl.13 strain at 0.01 (for HepaRG) and 0.1 (for hIPSC) multiplicity of infection (MOI) and incubated at 37 °C for 2 h. The cells were then washed three times with a fresh media and incubated with 1 mL of the appropriate fresh growth medium (herein, this time point is referred to as “T0” post-infection, p.i.). The culture supernatants (100 µL) were harvested at 24 h and 48 h p.i. and replaced with a fresh growth medium. The viral supernatants were titrated by limiting the dilution assays in BSR cells, as previously described [34]. Viral titers are expressed as 50% tissue culture infective doses (TCID50)/milliliter. All the experiments were performed independently in triplicate and repeated at least three times. Statistical analyses were conducted at 24 h and 48 h p.i. with viral titers equal to or above the threshold of detection (i.e., 1.5 log10 TCID50/mL), using the Kruskal–Wallis test and Graphpad Prism 8.4 (Graphpad Software Inc., La Jolla, CA, USA).

2.6. Mice Infection Assays

Six- to eight-week-old female BALB/cJrj mice were purchased from Janvier Labs (Le Genest St Isle, France). Groups of 5–6 mice were inoculated subcutaneously or intranasally with a 1 × 105 plaque-forming unit (PFU) of the SB or Cl.13 viral strains. Subcutaneous inoculations were performed on unanesthetized mice in the ventral region under a 100 µL volume. Intranasal inoculations were performed on mice anaesthetized with an intraperitoneal injection of Ketamine (60 mg/kg) and Xylazine (2 mg/kg). Ten microliters of inoculum were instilled in each nare. Three animals were enrolled in PBS-inoculated control groups. The clinical signs and survival rates were recorded daily over 15 days p.i. Mice showing severe clinical signs (ruffled fur, hunched posture, loss of >12% of their initial body weight) were humanely euthanized, whereas all the surviving mice were euthanized at the end of the experiments. The whole brain and liver were collected from the euthanized mice and frozen for RVFV RT-qPCR or, for the brain, fixed in 3.7% formaldehyde for immunohistochemistry analyses. The blood sera (250 µL/sampling) were collected at D0, D3, D6, and D10 p.i. Each experiment was performed independently twice for each viral strain, and in two different laboratories (ANSES and Institut Pasteur in Paris). The data from these two
experiments were similar and merged. Statistical analyses (Gehan–Breslow–Wilcoxon test) and Kaplan–Meier survival plots were conducted using Graphpad Prism 8.4.

2.7. RVFV RT-qPCR

The collected blood sera (100 µL) were directly mixed with 400 µL of AVL buffer from the QIAamp Viral RNA kit (Qiagen, Courtaboeuf, France). The whole brain and liver of euthanized mice were weighed and homogenized in a 500 µL DMEM using Tissue Lyser II (Qiagen). The viral RNAs were purified using the QIAamp Viral RNA kit (Qiagen) following the manufacturer’s protocol. The detection of the RVFV M segment was conducted by RT-qPCR using the SuperScript III Platinum One-Step qRT-PCR kit (Thermo Fisher Scientific, Villebon-sur-Yvette, France), as described elsewhere [35,36]. The efficiencies were estimated from the standard curves based on ten-fold dilutions of each viral stock, and were used to convert the Ct values to PFU-per-milliliter equivalents (eqPFU/mL) for the sera, or PFU-per-gram equivalents (eqPFU/g) for the tissues. Wilcoxon–Mann–Whitney test analyses were conducted using R software.

2.8. RVFV Serological Assays (ELISA)

The sera from the SB- and Cl.13-infected mice were tested for the presence of anti-RVFV IgG and IgM antibodies with in-house ELISA assays, as described previously [35,37]. Briefly, the IgG antigens were prepared from the MP-12 RVFV-infected cells while the IgM antigens were made from the MP-12 RVFV-infected cells and their supernatants. The negative controls without antigens correspond to the uninfected cells treated like the previous ones.

For the in-house IgG ELISA assay, 96-well culture plates Nunc MaxisorpTM (Thermo Fisher Scientific, Villebon-sur-Yvette, France) were coated with 100 µL of RVFV antigens (diluted 1:500 in PBS 0.01% Sodium Azide, Sigma-Aldrich, Merck, Saint-Quentin Fallavier, France) or negative-control antigens, and incubated overnight at 4 °C. The plates were then washed three times with 300 µL of PBS 0.05% Tween20 (PBS-T) (Euromedex, Souffelweyersheim, France), and the individual mouse sera were diluted 1:100 in PBS-T 5% skimmed milk powder (w/v) (PBS-T-M) and incubated at 37 °C for 1 h on coated plates. The plates were then washed three times with PBS-T and incubated at 37 °C for 1 h with HRP-conjugated rabbit anti-mouse IgG (whole molecule) (SigmaA9044) diluted 1:5000 in PBS-T-M. Finally, the plates were washed six times with PBS-T and the horseradish peroxidase (HRP) activity was revealed using the 3,3′,5,5′-tetramethylbenzidine (TMB) substrate (Life Technology). The chromogenic reaction was interrupted by adding 10.6% orthophosphoric acid (100 µL/well) (Alfa Aesar, Thermo Fisher Scientific, Villebon-sur-Yvette, France). The optical density (OD) was measured at 450 nm using a TECAN microplate reader. The adjusted OD450 values were calculated by subtracting the OD450 value of the negative Ag-coated wells (background) from that corresponding to those coated with the RVFV IgG antigens.

An in-house anti-RVFV IgM ELISA assay was developed using the capture ELISA method. Briefly, the micro-titer plates (Maxisorp, Nunc, Thermo Fisher Scientific, Villebon-sur-Yvette, France) were coated with a rabbit anti-mouse IgM (µ-chain specific) antibody (SAB3701197 Sigma-Aldrich, Merck, Saint-Quentin Fallavier, France) (100 µL/well, diluted 1:400 in PBS 0.01% Sodium Azide), and incubated overnight at 4 °C. The plates were then washed three times with PBS-T and the mouse sera (100 µL/well, diluted 1:100 in PBS-T-M) were added into two adjacent wells (even- and odd-numbered columns). After 1 h at 37 °C, the plates were washed with PBS-T and coated with 100 µL/well of the RVFV antigens (even-numbered columns) or negative-control antigens (odd-numbered columns). After 1 h of incubation at 37 °C, the cells were washed three times and incubated for 1 h at 37 °C with 100 µL/well of hyperimmunized sera from a hamster infected with the ZH501 RVF strain (dilution 1:2000 in PBS-T-M). The cells were then washed three times and incubated for 1 h at 37 °C with 100 µL of a goat anti-hamster IgG (H + L)-HRP conjugated antibody
(1:3000 in PBS-T-M) (Thermo Fisher Scientific). The OD was measured and calculated as described above for the RVFV IgG.

2.9. Immunohistochemistry (IHC)

The brain tissues of the infected or non-infected mice were embedded in paraffin and cut into 3 µm thick sections. The sections were treated with a BOND Epitope Retrieval Solution 1 (ready to use, citrate-based pH 6, epitope retrieval solution, AR9961, Leica Biosystems, Nanterre, France). An IHC detection of the RVFV-infected cells was performed with a polyclonal rabbit antibody raised against RVFV N-protein [38] diluted at 1:2000 in a Bond TM Primary Antibody Diluent (Leica Biosystems, Nanterre, France). The immunoreactive cells were revealed with a biotinylated goat anti-rabbit IgG secondary antibody at a 1:600 dilution (E0432, Dako, Agilent, Les Ulis, France). The biotin signal was detected using a Bond Intense R Detection System (DS9263, Leica Biosystems, Nanterre, France). The morphology of the microglial cells was assessed by immunohistochemistry using a rabbit anti-Iba1 primary antibody (#01919741, Wako chemical, Neuss, Germany, dilution 1:1000), as previously described [39]. The IHC analyses were conducted on consecutive sections and included the appropriate negative controls (an omission of the first antibody and non-infected brain tissues).

3. Results

3.1. The RVFV SB and Cl.13 Strains Are Lethal for Mice When Administered Intranasally

In order to assess whether the mortality rate depends on the route of administration, we inoculated BALB/c immunocompetent mice with 1 × 10^3 PFU of either an RVFV SB or Cl.13 live-attenuated strain by subcutaneous (SC) or intranasal (IN) routes. We observed that 60% of the SB-IN-infected mice died between days 5 and 7 post-infection (p.i.), while 40% of them survived until day 15 p.i. (Figure 1A). The kinetics of the mortality of the Cl.13-IN-infected mice were slightly delayed compared to the SB and reached 65% on day 15 p.i. (Figure 1B). It is of note that the SC inoculation induced a very low mortality (only 1/17 mice with SB; p < 0.001 for both viruses, Figure 1). We concluded that an IN administration leads to a higher mortality rate compared to an SC inoculation, regardless of the attenuated RVFV strain used.

![Figure 1. Survival rates of BALB/c mice intranasally or subcutaneously infected with the SB or Cl.13 vaccine strain. Kaplan–Meier survival plots of BALB/c mice subcutaneously (SC) or intranasally (IN) inoculated with 1 × 10^3 PFU of the Smithburn (A) or Clone 13 (B) strain. For both RVFV strains, the IN route of infection led to higher mortality rates than SC inoculation. Survival curves were compared using the Gehan–Breslow–Wilcoxon test (**: p < 0.001). n: number of mice per condition from, at least, two independent experiments.](image)

3.2. Intranasal Exposure of SB Induces Higher Viral Load Than the SC Inoculation

We then measured by the RT-qPCR the serum viral load of the mice who had been IN or SC infected with the SB or Cl.13 strain at D3, D6, and D10 p.i. The SB-inoculated mice displayed significantly higher viral loads after the IN than SC inoculation at D3 and D6 p.i.
(Figure 2A; p < 0.0001 or p < 0.05). By contrast, the Cl.13-infected mice showed a very low and inconsistent serum viral load at all the time points (Figure 2B).

Figure 2. Intranasally SB-infected mice display higher viremia than those subcutaneously infected. The graphs report the viral loads (expressed as eqPFU/mL) in the sera of intranasally (IN)- or subcutaneously (SC)-infected mice with the SB (A) or Cl.13 (B) strain, collected at D3 (n: SB-IN = 25; SB-SC = 17; Cl.13-IN = 11; and Cl.13-SC = 11), D6 (n: SN-IN = 15; SB-SC = 17; Cl.13-IN = 11 and Cl.13-SC = 11) and D10 (n: SN-IN = 10; SB-SC = 16; Cl.13-IN = 11; and Cl.13-SC = 11) p.i. Dashed lines indicate the threshold of virus detection \[ log_{10} (eqPFU/mL) = 1.049 \] for SB and 0.895 for Cl.13. Negative sera are shown below these lines for each virus at half the value of their detection limits. For SB data, statistical analyses were performed using Wilcoxon–Mann–Whitney test (*: p < 0.05; ****: p < 0.0001 and ns: not significant).

Finally, we evaluated the immune response against an SB or Cl.13 infection in the IN- or SC-infected mice by measuring the titers of the anti-RVFV IgM and IgG by an ELISA at D0, D3, D6, D10, and D15 p.i. We found that, regardless of the strain and the route of administration, all the mice raised anti-RVFV IgM antibodies by D6, while the first IgG-positive mice were detected on day 10, with a higher frequency in SB- than in Cl.13-infected mice (12/17 vs. 1/12, respectively, Fisher’s test \[ p = 0.0018 \]; Table 1). These results indicate that both SB and Cl.13 induce an immune response against RVFV.

Table 1. Seroconversion of intranasally and subcutaneously infected mice. The presence of anti-RVFV IgM and IgG antibodies in SB- and Cl.13-infected mice was detected by ELISA assays at D0, D3, D6, D10, and D15 p.i. The table indicates the number of IgM or IgG positive mice as well as the total number of mice analyzed at each time point and condition.
3.3. SB and Cl13 Strains Are Detected in the Brain of IN-Infected Mice

To study the dissemination of the SB and Cl.13 infections, we measured the viral loads in the whole brain and liver of IN-infected mice that were moribund and euthanized between D5 and D7 p.i. for SB and D6 and D13 p.i. for Cl.13. Notably, while both strains were detected in the two organs, the viral loads were significantly higher in the brain compared to the liver (log_{10} (eqPFU/g) = 11 vs. 2 for SB and 7 vs. 3 for Cl.13, respectively, \( p < 0.0001 \) and \( p < 0.05 \); Figure 3).

**Figure 3.** SB and Cl.13 display a higher viral load in the brain than in the liver of IN-infected mice. The graphs report the viral loads (expressed as eqPFU/g) in the brains and livers of euthanized mice intranasally (IN) infected with SB ((A); \( n = 15 \)) or Cl.13 ((B); \( n = 6 \)). Mice were euthanized when moribund between D5 and D7 p.i. for SB and D6 and D13 p.i. for Cl.13. Negative sera are shown below these lines for each virus at half the value of their detection limits. Statistical analyses were performed using Wilcoxon-Mann–Whitney test (*: \( p < 0.05 \); ****: \( p < 0.0001 \)).

These results indicate that SB and Cl.13 were able to disseminate and replicate more efficiently in the brain than in the liver of IN-infected mice. Notably, this difference in the viral loads was much higher for SB- than Cl.13-IN-infected mice (9 vs. 4 log_{10} (eqPFU/g)). These findings were further confirmed by an immunohistochemistry assay using an antibody raised against the RVFV N-protein. A positive cytoplasmic labeling was detected in several areas of the brain of both the Cl.13- and SB-IN-infected mice (Figure 4) and we did not identify virus-specific labelled areas. Interestingly, positive cells were often clustered and less frequently scattered, with morphological features typical of neurons of different sizes and of glial cells (Figure 4a,c). Immunolabelling with an anti-Iba1 antibody revealed the marked activation of microglial cells in the Cl.13-infected mice (Figure 4d), while the activation was mild in the SB-infected mice (Figure 4b).

3.4. RVFV SB Attenuated Strain Is Highly Replicative in Human Neural and Liver Cells

To further characterize the SB and Cl.13 strains, we assessed their replication in human pluripotent stem cells differentiated into neural cells (neural hiPCs) or human hepatocytes (HepaRC) at 24 h and 48 h p.i. SB displayed much higher viral titers than Cl.13 in both of the cell types and at both time points (Figure 5), suggesting that the SB strain has a stronger replication capacity than Cl.13.
sizes and of glial cells (Figure 4a,c). Immunolabelling with an anti-Iba1 antibody revealed the marked activation of microglial cells in the Cl.13-infected mice (Figure 4d), while the activation was mild in the SB-infected mice (Figure 4b).

**Figure 4.** Brain of SB- and Cl.13-IN-infected mice displays N-protein-positive cells and activated microglia. Mice intranasally infected with the SB (a,b) or Cl.13 (c,d) RVFV strains, or inoculated with PBS (e,f) were euthanized at day 6–10 (Cl.13) or day 5–7 (SB) p.i. when moribund, or day 20 post-inoculation (PBS) and their brain was analyzed by immunohistochemical staining against RVFV N (a,c,e) and Iba1 (b,d,f) proteins. Representative low magnification (×4) images show immunoreactivity to RVFV N-protein in the cranioventral portion of the brain of SB-infected mice (a) and the midbrain of Cl.13-infected mice (c) and compared to uninfected controls (e). Higher magnification insets (×20) show cells with morphological features of neurons (arrows) and glial cells (arrowheads). Microglial reactivity assessed by Iba1 staining was mild in SB-infected mice (b) and more pronounced in Cl.13-infected mice with activated microglial cells (d), inset. Bars: 200 µ in low magnification images and 50 µ in high magnification insets.
We showed that both strains are virulent in immunocompetent mice when administered intranasally. The SB-infected mice succumbed more rapidly to infection than the Cl.13-infected mice, although the final survival rate was similar (40% vs. 35%) for both of the strains. The difference in the lethality kinetics could be explained by the higher replicative capacity of the SB compared to Cl.13. Indeed, we found higher viral loads in the sera and brain of the SB-IN-infected mice, and higher viral titers in the hIPSCs and HepaRG immunocompetent cells infected with the SB strain compared to those infected with the Cl.13 strain. The reduced in vitro and in vivo replicative capacity of Cl.13 and its rapid clearance from the sera of immunocompetent mice is probably due to the absence of a functional NSs protein, a key RVFV virulence factor that blocks the host innate immune pathway [20,40].

Interestingly, both strains displayed higher viral titers in the brain than in the liver of IN-infected mice. This could be explained by the ability of RVFV to target the neurons lining the nasal tract that, in turn, could give the virus direct access to the brain [26–29]. From there, both strains may then reach the liver where either their attenuated status and/or the rapid mice death could impair their efficient replication in this organ, thereby explaining their reduced viral titers. On the other hand, one could raise the hypothesis that the reduced replication activities of SB and Cl.13 are also due to the stronger innate immune control of the viral infections exerted by the liver compared to the brain [41]. Indeed, although the SB encodes a functional NSs (unlike Cl.13), its attenuation status, yet uncharacterized, may affect its replication capacity in an immunity-independent manner. This, combined with the strong innate immunity of the liver, could prevent an efficient viral replication of SB in this organ and not in the brain.

Moreover, since the SB strain was generated by multiple passages in the mouse brain, it is likely to be more neuro-adapted than Cl.13, which could explain why the viral loads between the brain and the liver are much higher in the SB- than Cl.13-IN-infected mice (9 vs. 4 log10 (eqPFU/g)). Previous studies have shown that, in several animal models, an
aerosol or IN exposure to RVFV leads mainly to severe neurological symptoms compared to peripheral infection routes [27,29,31,42–46]. However, most studies have used virulent RVFV strains at infectious doses that induce rapidly developing severe disease and death, making it difficult to study the impact of administration routes on the virulence and pathogenicity. The use of live-attenuated strains derived from pathogenic RVFV strains (e.g., SB, Cl.13, and MP12) with a reduced virulence and pathogenicity provide better experimental models for such comparisons [47–49].

Many of the current RVFV live-attenuated vaccines induce adverse effects. For this reason, several laboratories have started developing safer candidate vaccines using reverse genetic systems. For example, Wichgers Schreur et al. developed a candidate vaccine based on a four-segmented Rift Valley fever virus (vRVFV-4s) that does not induce mortality in mice infected by an IN exposure, unlike SB or Cl.13 [32,50]. Dodd and colleagues demonstrated that a single NSs deletion RVFV mutant (ΔNSs rRVFV) causes lethal encephalitis by an IN exposure [31], whereas Bird et al. showed that a double deletion RVFV lacking the NSs and NSm virulent genes (ΔNSs-ΔNSm rRVFV) appears safe and effective when inoculated subcutaneously, even though its virulence has not been tested by an IN exposure yet [49]. Overall, these and our data highlight the importance of investigating the pathogenicity and, more particularly, the neurovirulence of RVFV live-attenuated vaccines using a different route of transmission to ascertain their safety.

Finally, our study revealed that both SB and Cl.13 can infect the neurons and microglia in the brain of infected mice, in accordance with what was previously observed with other RVFV strains [22,51,52]. Microglia cells are one of the main type I IFN-producing cells, an important first line of defense against viral infections [53] and the lack of the NSs protein in Cl.13 reduces its ability to antagonize the host immune response [20,40]. Interestingly, we observed a pronounced IBA-1 labeling in the brain of the Cl.13-IN-infected mice, suggesting a significant activation of the microglia cells in response to the infection. Therefore, the active replication of Cl.13 in the brain together with its lack of a functional NSs protein may lead to a strong neuroinflammation that, in turn, could participate to virus-induced neuropathogenesis in Cl.13-IN-infected mice [54]. Overall, SB displays a high replication capacity and the ability to antagonize the IFN response and, thus, the microglial activation. This, in turn, may lead to a rapid neurological disease and the death of the infected animals. On the other hand, Cl.13 may replicate less efficiently than SB but cause a protracted central nervous system disease which is associated with neuroinflammation. Further brain anatomopathological and neuroinflammation analyses over the course of the SB and Cl.13 infection will certainly answer these questions.

Our study shows that both the SB and Cl.13 attenuated vaccine strains are lethal only when administered intranasally (and not subcutaneously) in immunocompetent mice. These findings carry important scientific implications not only for a better understanding of the correlation between viral pathogenicity and the route of administration of RVFV, but also for raising awareness during vaccination campaigns against RVFV in Africa, where both strains are routinely used during epizootics [17]. It is indeed of the utmost importance to take special precaution to contacts and aerosols during these practices.

**Author Contributions:** S.L., M.C., M.-P.C., C.T., L.C., C.P., N.A., C.B. and X.M. performed the experiments. S.L., M.C., M.-P.C., M.D.L.H., P.M., N.A., B.P., M.R., M.F., X.M. and F.A. designed the experiments and analyzed the data. M.C., A.T. and F.A. performed the statistical tests. F.A. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was funded by the Metaprogram FORESEE of the INRAe, the Ecole Pratique des Hautes Etudes, the Institut National de la Recherche pour l’agriculture, l’alimentation et l’environnement, the University of Lyon 1 and the French Government’s Investissement d’Avenir programme, Laboratoire d’Excellence “Integrative Biology of Emerging Infectious Diseases” (grant n°ANR-10-LABX-62-IBEID).
Institutional Review Board Statement: All animal work was carried out in accordance with the Directive 2010/63/EU on the protection of animals used for scientific purposes. Protocols were approved by the Anses/ENVA/UPEC and Institut Pasteur ethics committees and the French Ministry of Research [Apafis n° 17985 and 6463]. All efforts were made to minimize animal suffering.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data that support the findings of this study are available upon request.

Acknowledgments: We acknowledge the contribution of the BSL3 of SFR Biosciences Gerland Lyon Sud (UMS3444/US8). We thank the C2RA Animal Facility staff and the Histology Platform of the Institut Pasteur, particularly Magali Tichit and David Hardy. We thank Benjamin Brennan (MRC-University of Glasgow Centre for Virus Research, Glasgow, UK) and Odile Boespflug-Tanguy (AP-HP, National Reference Center for Leukodystrophies, Paris, France) for, respectively, providing us with anti-N RVFV antibody and Human embryonic fibroblasts. We also thank Alessia Armezzani for revising the manuscript, and members of our laboratories for useful suggestions.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References
1. Easterday, B.C.; Mc, G.M.; Rooney, J.R.; Murphy, L.C. The pathogenesis of Rift Valley fever in lambs. Am. J. Vet. Res. 1962, 23, 470–479. [PubMed]
2. Ikegami, T.; Makino, S. The pathogenesis of Rift Valley fever. Viruses 2011, 3, 493–519. [CrossRef] [PubMed]
3. Pepin, M.; Bouloy, M.; Bird, B.H.; Kemp, A.; Paweska, J. Rift Valley fever virus (Bunyaviridae: Phlebovirus): An update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet. Res. 2010, 41, 61. [CrossRef] [PubMed]
4. Rippy, M.K.; Topper, M.J.; Mebus, C.A.; Morrill, J.C. Rift Valley fever virus-induced encephalomyelitis and hepatitis in calves. Vet. Pathol. 1992, 29, 495–502. [CrossRef] [PubMed]
5. Laughlin, L.W.; Meeghan, J.M.; Strausbaugh, L.J.; Morens, D.M.; Watton, R.H. Epidemic Rift Valley fever in Egypt: Observations of the spectrum of human illness. Trans. R Soc. Trop. Med. Hyg. 1979, 73, 630–633. [CrossRef]
6. Madani, T.A.; Al-Mazrou, Y.Y.; Al-Jeffri, M.H.; Mishkhas, A.A.; Al-Rabeah, A.M.; Turkistani, A.M.; Al-Sayed, M.O.; Abodahish, A.A.; Khan, A.S.; Ksiazek, T.G.; et al. Rift Valley fever epidemic in Saudi Arabia: Epidemiological, clinical, and laboratory characteristics. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2003, 37, 1084–1092. [CrossRef]
7. McIntosh, B.M.; Russell, D.; dos Santos, I.; Gear, J.H. Rift Valley fever in humans in South Africa. S Afr. Med. J. 1980, 58, 803–806. [PubMed]
8. Drouin, A.; Chevalier, V.; Durand, B.; Balenghien, T. Vector Competence of Mediterranean Mosquitoes for Rift Valley Fever Virus: A Meta-Analysis. Pathogens 2020, 11, 503. [CrossRef]
9. Linthicum, K.J.; Britch, S.C.; Anyamba, A. Rift Valley Fever: An Emerging Mosquito-Borne Disease. Annu. Rev. Entomol. 2016, 61, 395–415. [CrossRef]
10. Brown, J.L.; Domnik, J.W.; Morrissy, R.L. Respiratory infectivity of a recently isolated Egyptian strain of Rift Valley fever virus. Infect. Immun. 1981, 33, 848–853. [CrossRef]
11. Smithburn, K.C.; Mahaffy, A.F.; Haddow, A.J.; Kitchen, S.F.; Smith, J.F. Rift Valley fever: accidental infections among laboratory workers. J. Immunol. 1949, 62, 213–227. [PubMed]
12. Ahmad, K. More deaths from Rift Valley fever in Saudi Arabia and Yemen. Lancet 2000, 356, 1422. [CrossRef]
13. Al-Hazmi, M.; Ayoola, E.A.; Abdurahman, M.; Banzal, S.; Ashraf, J.; El-Bushra, A.; Hazmi, A.; Abdullah, M.; Abbo, H.; Elamin, A.; et al. Epidemic Rift Valley Fever in Saudi Arabia: A clinical study of severe illness in humans. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2003, 36, 245–252. [CrossRef] [PubMed]
14. Davies, F.G. The historical and recent impact of Rift Valley fever in Africa. Am. J. Trop. Med. Hyg. 2010, 83, 73–74. [CrossRef] [PubMed]
15. Nanyingi, M.O.; Munyua, P.; Kiama, S.G.; Muchemi, G.M.; Thumbi, S.M.; Bitek, A.O.; Bett, B.; Muriithi, R.M.; Njenga, M.K. A systematic review of Rift Valley Fever epidemiology 1931–2014. Infect. Ecol. Epidemiol. 2015, 5, 28024. [CrossRef]
16. Dungu, B.; Lubisi, B.A.; Ikegami, T. Rift Valley fever vaccines: Current and future needs. Curr. Opin. Virol. 2018, 29, 8–15. [CrossRef]
17. Petrova, V.; Kristiansen, P.; Norheim, G.; Yimer, S.A. Rift Valley fever: Diagnostic challenges and investment needs for vaccine development. BMJ Glob. Health 2020, 5, e002694. [PubMed]
18. Botros, B.; Omar, A.; Elan, K.; Mohamed, G.; Soliman, A.; Salib, A.; Salman, D.; Saad, M.; Earhart, K. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J. Med. Virol. 2006, 78, 787–791. [CrossRef]
19. Muller, R.; Saluzzo, J.F.; Lopez, N.; Dreier, T.; Turell, M.; Smith, J.; Bouloy, M. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am. J. Trop. Med. Hyg. 1995, 53, 405–411. [CrossRef]
20. Ly, H.J.; Ikegami, T. Rift Valley fever virus NSs protein functions and the similarity to other bunyavirus NSs proteins. Virol. J. 2016, 13, 118. [CrossRef]
21. Makoschey, B.; van Kilsdonk, E.; Hubers, W.R.; Vrijenhoek, M.P.; Smit, M.; Wichgers Schreur, P.J.; Kortekaas, J.; Moulin, V. Rift Valley Fever Virus Clone 13 Is Able to Cross the Oxine Placental Barrier Associated with Foetal Infections, Malformations, and Stillbirths. *PLoS Negl. Trop. Dis.* 2016, 10, e004530. [CrossRef] [PubMed]

22. Smith, D.R.; Steele, K.E.; Shamblin, J.; Honko, A.; Johnson, J.; Reed, C.; Kennedy, M.; Chapman, J.L.; Hensley, L.E. The pathogenesis of Rift Valley fever virus in the mouse model. *Virology* 2010, 407, 256–267. [CrossRef] [PubMed]

23. Batista, L.; Jouvion, G.; Simon-Chazottes, D.; Houzelstein, D.; Burlen-Defranoux, O.; Boissiere, M.; Tokuda, S.; do Valle, T.Z.; Cumano, A.; Flaman, M.; et al. Genetic dissection of Rift Valley fever pathogenesis: Rvfs2 locus on mouse chromosome 11 enables survival to early-onset hepatitis. *Sci. Rep.* 2020, 10, 8734. [CrossRef] [PubMed]

24. Gommet, C.; Billecocq, A.; Jouvion, G.; Hasan, M.; Zaverucha do Valle, T.; Guillemer, L.; Blanchet, C.; van Rooijen, N.; Montaguetti, X.; Bouloy, M.; et al. Tissue tropism and target cells of NSs-deleted rift valley fever virus in live immunodeficient mice. *PLoS Negl. Trop. Dis.* 2011, 5, e1421. [CrossRef]

25. MacDonald, G.H.; Johnston, R.E. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. *J. Virol.* 2000, 74, 914–922. [CrossRef]

26. Barbeau, D.J.; Albe, J.R.; Nambulli, S.; Tilston-Lunel, N.L.; Hartman, A.L.; Lakdawala, S.S.; Klein, E.; Duprex, W.P.; McElroy, A.K. Rift Valley Fever Virus Infection Causes Acute Encephalitis in the Ferret. *mSphere* 2020, 5, e00798-20. [CrossRef]

27. Hartman, A.L.; Powell, D.S.; Bethel, L.M.; Caroline, A.L.; Schmid, R.J.; Oury, T.; Reed, D.S. Aerosolized rift valley fever virus causes fatal encephalitis in african green monkeys and common marmosets. *J. Virol.* 2014, 88, 2235–2245. [CrossRef]

28. Reed, C.; Lin, K.; Wilhelmsen, C.; Friedrich, B.; Nalca, A.; Keeney, A.; Donnelly, G.; Shamblin, J.; Hensley, L.E.; Olinger, G.; et al. Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development. *PLoS Negl. Trop. Dis.* 2013, 7, e2156. [CrossRef]

29. Reed, D.S.; Bethel, L.M.; Powell, D.S.; Caroline, A.L.; Hartman, A.L. Differences in aerosolation of Rift Valley fever virus resulting from choice of inhalation exposure chamber: Implications for animal challenge studies. *Pathog.* 2014, 71, 227–233. [CrossRef]

30. Kroeker, A.L.; Smid, V.; Embury-Hyatt, C.; Collignon, P.; Pinette, M.; Babiuk, S.; Pickering, B. Increased Susceptibility of Cattle to Intranasal RVFV Infection. *Front. Vet. Sci.* 2020, 7, 137. [CrossRef]

31. Dodd, K.A.; McElroy, A.K.; Jones, T.L.; Zaki, S.R.; Nichol, S.T.; Spiropoulou, C.F. Rift valley Fever virus encephalitis is associated with an ineffective systemic immune response and activated T cell infiltration into the CNS in an immunocompetent mouse model. *PLoS Negl. Trop. Dis.* 2014, 8, e2874. [CrossRef] [PubMed]

32. Wichgers Schreur, P.J.; van Keulen, L.; Kant, J.; Kortekaas, J. Four-segmented Rift Valley fever virus-based vaccines can be applied safely in ewes during pregnancy. *Vaccine* 2017, 35, 3123–3128. [CrossRef] [PubMed]

33. Brennan, B.; Li, P.; Elliott, R.M. Generation and characterization of a recombinant Rift Valley fever virus expressing a V5 protein. *Comp. Immunol. Microbiol. Infect.* 2001, 25, 1046–10481. [CrossRef]

34. Drosten, C.; Gottig, S.; Schilling, S.; Asper, M.; Panning, M.; Schmitz, H.; Gunther, S. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. *J. Clin. Microbiol.* 2002, 40, 2323–2330. [CrossRef]

35. Chrun, T.; Lacote, S.; Urien, C.; Jouneau, L.; Barc, C.; Bouguyon, E.; Contreras, V.; Ferrier-Rembert, A.; Peyrefitte, C.N.; Busquets, N.; et al. A Rift Valley fever virus Gn ectodomain-based DNA vaccine induces a partial protection not improved by APC targeting. *NPJ Vaccines* 2018, 3, 14. [CrossRef] [PubMed]

36. Drostoen, C.; Gottig, S.; Schilling, S.; Asper, M.; Panning, M.; Schmitz, H.; Gunther, S. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. *J. Clin. Microbiol.* 2002, 40, 2323–2330. [CrossRef]

37. Chrun, T.; Lacote, S.; Urien, C.; Richard, C.A.; Tenbusch, M.; Aubrey, N.; Pulido, A.; Lakdhar, L.; Marianneau, P.; Schwartz-Cornil, I. A DNA Vaccine Encoding the Gn Ectodomain of Rift Valley Fever Virus Protects Mice via a Humoral Response Decreased by DEC205 Targeting. *Front. Immunol.* 2019, 10, 860. [CrossRef]

38. Lozach, P.Y.; Kuhbach, A.; Meier, R.; Mancini, R.; Bitto, D.; Bouloy, M.; Helenius, A. DC-SIGN as a receptor for phleboviruses. *Cell Host Microbe* 2011, 10, 75–88. [CrossRef]

39. Verdun, F.; Roux, P.; Flament, P.; Fiette, L.; Bozza, F.A.; Simard, S.; Lemaire, M.; Plaud, B.; Shorte, S.L.; Sharshar, T.; et al. Phenotypic clustering: A novel method for microglial morphology analysis. *J. Neuroinflammation* 2016, 13, 153. [CrossRef]

40. Bouloy, M.; Janzen, C.; Vialat, P.; Khun, H.; Pavlovic, J.; Huerre, M.; Haller, O. Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. *J. Virol.* 2001, 75, 1371–1377. [CrossRef] [PubMed]

41. Gao, B.; Jeong, W.I.; Tian, Z. Liver: An organ with predominant innate immunity. *Hepatology* 2008, 47, 729–736. [CrossRef] [PubMed]

42. Booyes, D.A.; Schwarz, M.M.; Albe, J.R.; McMullen, C.M.; O’Malley, K.J.; Reed, D.S.; Hartman, A.L. Development of Rift valley fever encephalitis in rats is mediated by early infection of olfactory epithelium and neuroinvasion across the cribriform plate. *J. Virol.* 2001, 75, 1371–1377. [CrossRef] [PubMed]

43. Hickerson, B.T.; Westover, J.B.; Van Wettere, A.J.; Rigas, J.D.; Miao, J.; Conrad, B.L.; Motter, N.E.; Wang, Z.; Gowen, B.B. Pathogenesis of Rift Valley Fever Virus Aerosol Infection in STAT2 Knockout Hamsters. *Virobes* 2018, 10, 651. [CrossRef] [PubMed]

44. Scharton, D.; Bailey, K.W.; Vest, Z.; Westover, J.B.; Kumaki, Y.; Van Wettere, A.; Furuta, Y.; Gowen, B.B. Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. *Antiviral. Res.* 2014, 104, 84–92. [CrossRef] [PubMed]
45. Smith, D.R.; Bird, B.H.; Lewis, B.; Johnston, S.C.; McCarthy, S.; Keeney, A.; Botto, M.; Donnelly, G.; Shamblin, J.; Albarino, C.G.; et al. Development of a novel nonhuman primate model for Rift Valley fever. *J. Virol.* 2012, 86, 2109–2120. [CrossRef]

46. Wonderlich, E.R.; Caroline, A.L.; McMillen, C.M.; Walters, A.W.; Reed, D.S.; Barratt-Boytes, S.M.; Hartman, A.L. Peripheral Blood Biomarkers of Disease Outcome in a Monkey Model of Rift Valley Fever Encephalitis. *J. Virol.* 2018, 92, e01662-17. [CrossRef]

47. Meegan, J.M. The Rift Valley fever epizootic in Egypt 1977–1978. 1. Description of the epizoozotic and virological studies. *Trans. R Soc. Trop. Med. Hyg.* 1979, 73, 618–623. [CrossRef]

48. Caplen, H.; Peters, C.J.; Bishop, D.H. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. *J. Gen. Virol.* 1985, 66, 2271–2277. [CrossRef]

49. Bird, B.H.; Albarino, C.G.; Hartman, A.L.; Erickson, B.R.; Ksiazek, T.G.; Nichol, S.T. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. *J. Virol.* 2008, 82, 2681–2691. [CrossRef]

50. Wichgers Schreur, P.J.; Oreshkova, N.; Moormann, R.J.; Kortekaas, J. Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging. *J. Virol.* 2014, 88, 10883–10893. [CrossRef]

51. Hum, N.R.; Bourguel, F.A.; Sebastian, A.; Lam, D.; Phillips, A.M.; Sanchez, K.R.; Rasley, A.; Loots, G.G.; Weilhammer, D.R. MAVS mediates a protective immune response in the brain to Rift Valley fever virus. *PLoS Pathog.* 2022, 18, e1010231. [CrossRef] [PubMed]

52. Reed, C.; Steele, K.E.; Honko, A.; Shamblin, J.; Hensley, L.E.; Smith, D.R. Ultrastructural study of Rift Valley fever virus in the mouse model. *Virology* 2012, 431, 58–70. [CrossRef] [PubMed]

53. Chen, Z.; Zhong, D.; Li, G. The role of microglia in viral encephalitis: A review. *J. Neuroinflammation* 2019, 16, 76. [CrossRef] [PubMed]

54. Albe, J.R.; Boyles, D.A.; Walters, A.W.; Kujawa, M.R.; McMillen, C.M.; Reed, D.S.; Hartman, A.L. Neutrophil and macrophage influx into the central nervous system are inflammatory components of lethal Rift Valley fever encephalitis in rats. *PLoS Pathog.* 2019, 15, e1007833. [CrossRef] [PubMed]